USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent

The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer

Nanoform grant global starmap AI license to AstraZeneca

Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening

Cosmo and Glenmark sign distribution and license agreements for Winlevi in Europe and South Africa

Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries

GeoVax secures multi-product license for ProBioGen's AGE1.CR.pIX suspension cell line

The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types

USFDA accepts biologics license application for GC Biopharma's GC5107B

Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs

Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics

Astellas receives FDA priority review for Zolbetuximab biologics license application

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients

PrecisionLife Licenses University of Oxford data to discover personalised treatments for endometriosis patients

PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments

Eugia Pharma signs voluntary license with Medicines Patent Pool to develop generic version of Nilotinib Capsules

The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India

USFDA accepts biologics license application for Pfizer’s respiratory syncytial virus maternal vaccine candidate for priority review

This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency